Zion Market Research has published a
new report titled “General Anxiety Disorder Market by Therapeutics (Antidepressant,
Benzodiazepines and Others): U.S. Industry Perspective, Comprehensive Analysis
and Forecast, 2014 – 2020.” According to the report, The U.S. demand for
general anxiety disorder market was valued at USD 3,251 million in 2014, and is
expected to generate revenue of USD 3,775 million by end of 2020, growing at a
CAGR of 2.4% between 2015 and 2020.
Browse the full "General Anxiety Disorder Market by
Therapeutics (Antidepressant, Benzodiazepines and Others): U.S. Industry
Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and
Forecast 2014 – 2020" report at https://www.zionmarketresearch.com/report/general-anxiety-disorder-market
General anxiety
disorders or generalized anxiety disorders (GAD) usually happen along with
other physical or mental illnesses such as alcohol or substance abuse, which
might mask anxiety symptoms. In some scenario, these other illnesses treated
prior to person respond to treatment for the anxiety disorder. Efficient
therapies for general anxiety disorders are present, and ongoing research is
uncovering novel treatments that may aid most people with GAD.
Currently, U.S.
general anxiety disorders market is saturated as a variety of antidepressant
drugs are available on prescription for the similar symptom. Presently, general
anxiety disorders market is on a decline owing to weak pipeline of novel drugs,
patent expiry of major antidepressants and increasing number of cheap generic
drug variants in the market. U.S. stands for the major regional market for
anxiety disorder therapeutics worldwide.
General anxiety
disorder market includes several types of therapeutic segments such as
antidepressant, benzodiazepines and other therapeutics. Antidepressant was a
main therapeutic segment of general anxiety disorder market and accounted 38.6%
share of the total demand in 2014. This segment is further expected to continue
its dominance in market over the estimate period. Several kinds of medications
employed to treat general anxiety disorder. Antidepressants such as serotonin
norepinephrine reuptake inhibitor (SNRI) and selective serotonin reuptake
inhibitor (SSRI) classes, are the first-line medication treatments.
Benzodiazepines are the most common class of anti anxiety drugs and usually
employed only for relieving severe anxiety on a short-term basis. These are
medications alleviate anxiety by slowing down the central nervous system. Their
calming and relaxing effects have made them very popular in U.S. They are also
prescribed as muscle relaxants and sleeping pills.
Free
Request Sample @ https://www.zionmarketresearch.com/sample/general-anxiety-disorder-market
North America emerged as foremost
regional market for the global depression in 2014. This was mostly due to
presence of large population infected with many kinds of depression and anxiety
disorders. Some of the renowned players in this market include Eli Lilly
and Company, Sanofi S.A. Forest Laboratories, Inc., Johnson & Johnson H.
Lundbeck A/S, Merck & Co., Inc., Pfizer, Inc. are some of dominant players
in the market space.
The report segments the U.S. general anxiety disorder market
into:
U.S. General anxiety disorder Market: Therapeutics Segment
Analysis
• Antidepressant
• Benzodiazepines
• Others (Buspirone)
• Antidepressant
• Benzodiazepines
• Others (Buspirone)
About Us
Zion Market Research
is a market intelligence company providing global business information reports
and services. Our exclusive blend of quantitative forecasting and trends
analysis provides forward-looking insight for thousands of decision makers.
Zion Market Research experienced team of Analysts, Researchers, and Consultants
uses proprietary data sources and various tools and techniques to gather, and
analyze information. Our business offerings represent the latest and the most
reliable information indispensable for businesses to sustain a competitive
edge.
Contact US:
4283, Express Lane, Suite 634-143,
Sarasota, Florida 34249, United
States
Tel: +1-386-310-3803 GMT
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Tel: +1-386-310-3803 GMT
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: http://www.zionmarketresearch.com
No comments:
Post a Comment